Dr. Deborah Birx (‘Scarf Lady’) Lands New Pharma Job

Former White House Coronavirus Response Coordinator Dr. Deborah Birx, aka “Scarf Lady,” has landed a cushy new job in the pharmaceutical industry.

Birx is the new Chief Executive Officer of Armata Pharmaceuticals, Inc.

“Deborah L. Birx, M.D., was appointed Chief Executive Officer of Armata on July 10, 2023,” Birx’s bio on the company’s website read.

Birx also sits on the Armata Pharmaceuticals Board of Directors.

“Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections,” Armata Pharmaceuticals’ website reads.

Dr. Deborah Birx is Now the CEO of Armata Pharmaceuticals

“Deborah L. Birx, M.D., was appointed Chief Executive Officer of Armata on July 10, 2023.

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage… pic.twitter.com/ob5iyU9TYk

— Chief Nerd (@TheChiefNerd) July 22, 2023

Former top Covid adviser Dr. Deborah Birx is seamlessly transitioning to Big Pharma CEO.https://t.co/V9tTvw3X2x

— Kyle Becker (@kylenabecker) July 22, 2023

Armata Pharmaceuticals announced:

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”). The gross proceeds of the credit agreement at closing are $25 million before transaction‐related expenses. Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of the Company, effective immediately. Dr. Birx will also join Armata’s Board of Directors.

“I am thrilled to join Armata at this pivotal time in the Company’s development. I’m impressed with the scientific platform’s quality and the team’s commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company’s progress and drive value creation. The recent investment enables the advancement of AP‐PA02 and AP‐SA02 in Phase 2 clinical trials,” Birx stated.

Dr. Birx admitted in 2022 that she misled Americans about the efficacy of COVID-19 shots to prevent transmission.

“I knew these vaccines were not going to protect against infection,” Birx said on Fox News in July 2022.

Via Fox News:

Former White House COVID response coordinator Dr. Deborah Birx said she “knew” that COVID-19 vaccines “were not going to protect against infection” Friday on “Your World.”

DR. BIRX: I knew these vaccines were not going to protect against infection. And I think we overplayed the vaccines, and it made people then worry that it’s not going to protect against severe disease and hospitalization. It will. But let’s be very clear: 50% of the people who died from the Omicron surge were older, vaccinated. So that’s why I’m saying even if you’re vaccinated and boosted, if you’re unvaccinated right now, the key is testing and Paxlovid. It’s effective. It’s a great antiviral. And really, that is what’s going to save your lives right now if you’re over 70, which if you look at the hospitalizations, hospitalizations are rising steadily with new admissions, particularly in those over 70. And so if you live in the South – I know people keep talking about the fall – I’m worried about the South.

WATCH:

🚨 BREAKING: Dr. Deborah Birx Admits She Manipulated Data and Altered CDC Guidelines to Deceive President Trump.

"I knew these vaccines were not going to protect against infection and I think we overplayed the vaccines …"https://t.co/4vOw0AsBdG pic.twitter.com/peS79oZa63

— Joe Bell (@JoeBell) February 1, 2023